Show simple item record

dc.contributor.authorJones, Anthony K P
dc.contributor.authorWatabe, Hiroshi
dc.contributor.authorCunningham, Vin J
dc.contributor.authorJones, Terry
dc.date.accessioned2009-08-20T11:10:25Z
dc.date.available2009-08-20T11:10:25Z
dc.date.issued2004-10
dc.identifier.citationCerebral decreases in opioid receptor binding in patients with central neuropathic pain measured by [11C]diprenorphine binding and PET. 2004, 8 (5):479-85 Eur J Painen
dc.identifier.issn1090-3801
dc.identifier.pmid15324779
dc.identifier.doi10.1016/j.ejpain.2003.11.017
dc.identifier.urihttp://hdl.handle.net/10541/77993
dc.description.abstractCentral neuropathic pain (CNP) is pain resulting from damage to the central nervous system. Up till now, it has not been possible to identify a common lesion or pharmacological deficit in these patients. This preliminary study in a group of patients with CNP with predominantly post-stroke pain, demonstrates that there is significantly less opioid receptor binding in a number of cortical and sub-cortical structures that are mostly, but not exclusively, within the medial pain system in patients compared to age-matched pain-free controls. The reductions in opioid receptor binding within the medial system were observed mainly in the dorsolateral (Brodman area 10) and anterior cingulate (Brodman area 24 with some extension into area 23) and insula cortices and the thalamus. There were also reductions in the lateral pain system within the inferior parietal cortex (Brodman area 40). These changes in binding could not be accounted for by the cerebral lesions shown by CT or MRI, which were outside the areas of reduced binding and the human pain system. To our knowledge this is the first systematic demonstration of a reduction in opioid receptor-binding capacity in neurones within the human nociceptive system in patients with CNP. This may be a key common factor resulting in undamped nociceptor activity within some of the structures that are predominantly within the medial nociceptive system. If confirmed, these findings may explain why certain patients with CNP require high doses of synthetic opiates to achieve optimum analgesia. The findings also raise the possibility of new pharmacological approaches to treatment.
dc.language.isoenen
dc.subject.meshAged
dc.subject.meshAnalgesics
dc.subject.meshBinding, Competitive
dc.subject.meshCerebral Cortex
dc.subject.meshDiprenorphine
dc.subject.meshDown-Regulation
dc.subject.meshDrug Resistance
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshModels, Neurological
dc.subject.meshNeural Pathways
dc.subject.meshOpioid Peptides
dc.subject.meshPain, Intractable
dc.subject.meshPositron-Emission Tomography
dc.subject.meshPredictive Value of Tests
dc.subject.meshRadioligand Assay
dc.subject.meshReceptors, Opioid
dc.subject.meshStroke
dc.subject.meshThalamus
dc.titleCerebral decreases in opioid receptor binding in patients with central neuropathic pain measured by [11C]diprenorphine binding and PET.en
dc.typeArticleen
dc.contributor.departmentHuman Pain Research Laboratory, University of Manchester Rheumatic Diseases Centre, Clinical Sciences Building, Hope Hospital, Eccles Old Road, Salford M6 8HD, UK. anthony.jones@man.ac.uken
dc.identifier.journalEuropean Journal of Painen
html.description.abstractCentral neuropathic pain (CNP) is pain resulting from damage to the central nervous system. Up till now, it has not been possible to identify a common lesion or pharmacological deficit in these patients. This preliminary study in a group of patients with CNP with predominantly post-stroke pain, demonstrates that there is significantly less opioid receptor binding in a number of cortical and sub-cortical structures that are mostly, but not exclusively, within the medial pain system in patients compared to age-matched pain-free controls. The reductions in opioid receptor binding within the medial system were observed mainly in the dorsolateral (Brodman area 10) and anterior cingulate (Brodman area 24 with some extension into area 23) and insula cortices and the thalamus. There were also reductions in the lateral pain system within the inferior parietal cortex (Brodman area 40). These changes in binding could not be accounted for by the cerebral lesions shown by CT or MRI, which were outside the areas of reduced binding and the human pain system. To our knowledge this is the first systematic demonstration of a reduction in opioid receptor-binding capacity in neurones within the human nociceptive system in patients with CNP. This may be a key common factor resulting in undamped nociceptor activity within some of the structures that are predominantly within the medial nociceptive system. If confirmed, these findings may explain why certain patients with CNP require high doses of synthetic opiates to achieve optimum analgesia. The findings also raise the possibility of new pharmacological approaches to treatment.


Files in this item

This item appears in the following Collection(s)

Show simple item record